prostate cancer

Preclinical Analysis of Resistance and Cross-Resistance to Low-Dose Metronomic Chemotherapy.

Published June 4, 2013

Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.

Invest New Drugs. 2013 Jun 2;
Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U

Low-dose metronomic chemotherapy is an emerging form of chemotherapy with distinct… Continue reading →

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis.

Published May 31, 2013

Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.

PLoS One. 2013; 8(5): e64275
Zhong L, Pon V, Srinivas S, Nguyen N, Frear M, Kwon S, Gong C, Malmstrom R, Wilson L

Docetaxel is an established first-line… Continue reading →

Identifying Cognitive and Demographic Variables That Contribute to Carer Burden in Dementia.

Published May 30, 2013

Identifying Cognitive and Demographic Variables That Contribute to Carer Burden in Dementia.

Dement Geriatr Cogn Disord. 2013 May 23; 36(1-2): 43-49
Miller LA, Mioshi E, Savage S, Lah S, Hodges JR, Piguet O

Background/Aims: Carer burden has been associated… Continue reading →

Discord of Measurements in Assessing Depression Among African Americans With Cancer Diagnoses.

Published May 18, 2013

Discord of Measurements in Assessing Depression among African Americans with Cancer Diagnoses.

Int J Cult Ment Health. 2013 Jan 1; 6(1): 58-71
Zhang AY, Gary F

This study examined the level of agreement among the Center for Epidemiologic Studies-Depression… Continue reading →

In Vitro Model Systems to Study Androgen Receptor Signaling in Prostate Cancer.

Published May 7, 2013

In vitro model systems to study androgen receptor signaling in prostate cancer.

Endocr Relat Cancer. 2013 Apr; 20(2): R49-64
Sampson N, Neuwirt H, Puhr M, Klocker H, Eder IE

Prostate cancer (PCa) is one of the most common causes… Continue reading →

Current Status of 5?-Reductase Inhibitors in Prostate Disease Management.

Published April 25, 2013

Current status of 5?-reductase inhibitors in prostate disease management.

Korean J Urol. 2013 Apr; 54(4): 213-9
Kang DI, Chung JI

The key enzyme in the androgen synthesis and androgen receptor pathways is 5?-reductase (5-AR), which occurs as three isoenzymes.… Continue reading →

Prostate Cancer and Sexual Function.

Published April 19, 2013

Prostate Cancer and Sexual Function.

World J Mens Health. 2012 Aug; 30(2): 99-107
Hyun JS

Prostate cancer is now ranked fifth in incidence among cancers in Korean adult males. This is attributable to the more Westernized dietary style which… Continue reading →

Second-Line Treatment of Metastatic Prostate Cancer. Prednisone and Radiotherapy for Symptom Relief.

Published April 18, 2013

Second-line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief.

Prescrire Int. 2013 Mar; 22(136): 74-8

First-line treatment based on androgen suppression is initially very effective in relieving the symptoms of metastatic prostate cancer. When androgen suppression… Continue reading →

Men With Prostate Cancer Make Positive Dietary Changes Following Diagnosis and Treatment.

Published March 23, 2013

Men with prostate cancer make positive dietary changes following diagnosis and treatment.

Cancer Causes Control. 2013 Mar 22;
Avery KN, Donovan JL, Gilbert R, Davis M, Emmett P, Down L, Oliver S, Neal DE, Hamdy FC, Lane JA

PURPOSE:… Continue reading →

Simultaneous Quantitation of Venlafaxine and Its Main Metabolite, O-Desmethylvenlafaxine, in Human Saliva by HPLC.

Published March 16, 2013

Simultaneous quantitation of venlafaxine and its main metabolite, O-desmethylvenlafaxine, in human saliva by HPLC.

J Sep Sci. 2013 Mar 12;
Dziurkowska E, Wesolowski M

Venlafaxine is used for the treatment of major depression and generalized anxiety disorders. Because its… Continue reading →